Therefore, immune based therapies such as TSPO ligands and IFN-β that counter excessive microglia-mediated neuroinflammatory responses and pathological angiogenesis may have an important role in the future clinical management of retinal disorders such as RP and AMD. The gene discussed is IFNB1; the disease is age-related macular degeneration.